Skip to main content

Table 1 Data analysis of included studies

From: Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients

Study N Male Female Age (average) Resource of tumor Volume of MPE(N) Quality of Life (KPS) End point
NSCLC SCLC Gastrointestinal tumor Breast cancer Lymphoma Others
Changjie H 2001 [15] 60 44 16 30–76 27 4 11 10 8 Moderate-large > 60 ORR, DCR, AEs
Xiuzhi Y 2001 [16] 60 24 36 40–75 56 0 0 0 4 ORR, DCR, AEs
Zhuo S 2004 [17] 62 55 0 0 0 7 > 50 ORR, DCR, QOL, AEs
Junyan W 2005 [18] 82 57 25 33–78 68 0 10 0 4 > 50 ORR, DCR, AEs
Haiying X 2009 [19] 63 35 28 35–71 63 0 0 0 0 > 60 ORR, DCR, AEs
Xiaoxia H 2009 [20] 72 65 0 0 0 7 Small (8)
Moderate (39)
Large (25)
> 60 ORR, DCR, QOL, AEs
Lizheng C 2009 [21] 86 62 24 25–75 23 0 27 17 8 11 Large(29)
Moderate(57)
> 60 ORR, DCR, AEs
Jinguang C 2009 [22] 62 28 34 41–77 52 10 0 0 0 0 > 60 ORR, DCR, AEs
Junfeng W 2010 [23] 82 48 34 30–80 54 0 15 0 13 Large(56)
Moderate(26)
> 60 ORR, DCR, AEs
Jingping Z 2010 [24] 124 80 44 47–73 124 0 0 0 0 Large(84)
Moderate(40)
> 60 ORR, DCR, AEs
Cheng X 2010 [25] 62 28 34 19–81 40 0 9 13   > 70 ORR, DCR, AEs
Fang S 2011 [26] 60 31 29 38–76 41 8 2 7 2 0 Large(34)
Moderate(17)
> 40 ORR, DCR, QOL, AEs
Xueling L 2011 [27] 68 40 28 30–75 40 10 8 0 10 > 60 ORR, DCR, AEs
Yan Q 2011 [28] 76 45 31 46–77 76 0 0 0 0 > 60 ORR, DCR, AEs
Li J 2013 [29] 73 40 33 35–74 31 16 26 0 0 Large(41)
Moderate(32)
> 60 ORR, DCR, QOL, AEs
Lijie H 2014 [30] 60 38 22 39–78 60 0 0 0 0 Large > 50 ORR, DCR, QOL, AEs
Miao H 2016 [31] 61 40 21 38–75 42 0 8 6 5 Large > 60 ORR, DCR, AEs
Baohua Y 2017 [32] 66 35 31 42–76 > 60 RR, DCR
  1. N number of patients, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, MPE malignant pleural effusions, KPS karnofsky physical status score, ORR objective response rate, DCR, disease control rate, QOL quality of life, AEs adverse effects